Novo Nordisk's $450 Mistake: Patent Lapse Opens Canadian Market for Generic Semaglutide

Novo Nordisk's Canadian Patent Lapse

• ⚠️ Novo Nordisk has lost its exclusive patent for semaglutide (Ozempic and Wegovy) in Canada due to a failure to pay a $450 licensing fee.
• 🗓️ The patent, which could have lasted until 2032, lapsed in 2020 after Novo Nordisk missed a payment deadline following a notice in 2019.
• 🇨🇦 The last recorded fee payment for the patent was in 2018.

Hims & Hers Health Enters the Market

• 🚀 Hims and Hers Health has announced plans to expand into Canada in 2026.
• 💊 The telehealth company intends to offer a generic version of semaglutide, an exact copy of Novo Nordisk's blockbuster drugs.
• 📈 This move is strategically timed to capitalize on the significant Canadian weight loss drug market.

Market Impact and Company Statements

• 💰 The semaglutide market generated $1.18 billion in 2024 and is projected to exceed $4 billion within the next decade.
• 🗣️ Novo Nordisk declined to label the patent lapse as a mistake, stating that exclusivity ending is part of a drug's normal lifecycle.
• ✅ Hims and Hers confirmed they are working with an approved partner to comply with Canadian laws and regulations, with expectations of launching a product in 2026.